AXIOS June 4, 2024
Tina Reed

The evidence of new obesity and diabetes drugs’ smashing success can now be seen in grocery store aisles.

Why it matters: Food giants are rolling out new and reformulated products appealing to the changing appetites of the fast-growing number of people prescribed drugs like Novo Nordisk’s Ozempic and Wegovy — and experts say this could shift American diets more broadly.

The big picture: It’s thought the drugs known as GLP-1 agonists help patients lose weight by slowing down stomach emptying, allowing them to get full faster and for longer.

  • But that can also make it harder to get necessary nutrients, experts say.
  • GLP-1 users also have reported changing tastes, with high-fat and sweet foods becoming less appealing for some.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
Walmart's '24 healthcare exit: 10 notes
What big retailers did in healthcare in 2024
How Trauma-Informed Design Principles Can Be Health-Ful for All of Us – Learning from IKEA
Walmart health and wellness leader to exit role
Instacart inks another healthcare partnership

Share This Article